Getinge GETI B
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Maintain the current position; investors looking to add can do so gradually after the strong report, but a larger increase may be better timed after Q3 confirms that margin and order momentum persist without meaningful one-offs.
Strong Q2 with improved underlying margin and cash flow supports continued HOLD while awaiting confirmation that the trend is sustainable.
Sentiment has strengthened further on the product launch and ABG upgrade, although the Nordea downgrade and new short position provide some counterweight.
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 18 Jul 2026 — Q2 delivered 4.6% organic growth and +6.2% order intake, with adj. EBITA margin 17.6% (15.2% excl. tariff refund/FX) including a ~SEK 336m one-off. Free cash flow was SEK 1,001m and FY 3–5% organic growth guidance was…
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Getinge AB is a Swedish medtech company providing equipment and solutions to hospitals and life science customers globally. The company is profitable with improving underlying margins, but reported results are affected by FX/tariffs and recurring regulatory/quality risks (especially in the US).
Bull case
Strong order intake, improved underlying margin and sharply higher free cash flow indicate the profitability lift can prove sustainable.
Bear case
Parts of the Q2 lift were one-off driven and historical regulatory challenges plus Life Science volatility may pressure valuation if the trend is not confirmed.
Why this signal
Strong Q2 with improved underlying margin and cash flow supports continued HOLD while awaiting confirmation that the trend is sustainable.
Recent news
Getinge launched Torin Plan Optimizer on 8 September, an AI-based surgical planning solution. ABG Sundal Collier upgraded to Buy with a 285 SEK target while Nordea downgraded to Hold. Management stated US quality issues are expected to be resolved in 2027 with normal valuation from 2028.